Current status on the development of pseudoviruses for enveloped viruses - PubMed (original) (raw)

Review

Current status on the development of pseudoviruses for enveloped viruses

Qianqian Li et al. Rev Med Virol. 2018 Jan.

Abstract

Emerging and reemerging infectious diseases have a strong negative impact on public health. However, because many of these pathogens must be handled in biosafety level, 3 or 4 containment laboratories, research and development of antivirals or vaccines against these diseases are often impeded. Alternative approaches to address this issue have been vigorously pursued, particularly the use of pseudoviruses in place of wild-type viruses. As pseudoviruses have been deprived of certain gene sequences of the virulent virus, they can be handled in biosafety level 2 laboratories. Importantly, the envelopes of these viral particles may have similar conformational structures to those of the wild-type viruses, making it feasible to conduct mechanistic investigation on viral entry and to evaluate potential neutralizing antibodies. However, a variety of challenging issues remain, including the production of a sufficient pseudovirus yield and the inability to produce an appropriate pseudotype of certain viruses. This review discusses current progress in the development of pseudoviruses and dissects the factors that contribute to low viral yields.

Keywords: HIV; MLV; VSV; lentiviral vector; packaging system; pseudovirus.

Copyright © 2017 John Wiley & Sons, Ltd.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interest.

Similar articles

Cited by

References

    1. Sanders DA. No false start for novel pseudotyped vectors. Curr Opin Biotechnol. 2002;13(5):437‐442. - PubMed
    1. Clapham PR. Vesicular stomatitis virus pseudotypes of retroviruses. Methods Mol Biol. 1992;8:95‐102. 10.1385/0-89603-191-8:95 - DOI - PubMed
    1. Zhang L, Li Q, Liu Q, Huang W, Nie J, Wang Y. A bioluminescent imaging mouse model for Marburg virus based on a pseudovirus system. Hum Vaccin Immunother. 2017;13(8):1‐7. 10.1080/21645515.2017.1325050 - DOI - PMC - PubMed
    1. Welch SR, Guerrero LW, Chakrabarti AK, et al. Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems. Antiviral Res. 2016;136:9‐18. 10.1016/j.antiviral.2016.10.007 - DOI - PubMed
    1. Sehr P, Rubio I, Seitz H, et al. High‐throughput pseudovirion‐based neutralization assay for analysis of natural and vaccine‐induced antibodies against human papillomaviruses. PLoS One. 2013;8(10):e75677 10.1371/journal.pone.0075677 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources